A COMPREHENSIVE REVIEW OF SYSTEMIC FACTORS ASSOCIATED WITH PERI-IMPLANT DISEASES
Review Article diabetes mellitus and non-diabetic controls. J Periodontol. 2007; 78( 11): 2112-2119.
31. Javed F, Al Amri MD, Al-Kheraif AA, et al. Efficacy of nonsurgical periodontal therapy with adjunct nd: Yag laser therapy in the treatment of periodontal inflammation among patients with and without type 2 diabetes mellitus: A short-term pilot study. J Photochem Photobiol B. 2015; 149:230-234.
32. Javed F, Al-Kheraif AA, Salazar-Lazo K, et al. Periodontal inflammatory conditions among smokers and neversmokers with and without type 2 diabetes mellitus. J Periodontol. 2015; 86( 7): 839-846.
33. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001; 27( 5 Pt 1): 535-542.
34. Fong Y, Edelstein D, Wang EA, Brownlee M. Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. Diabetologia. 1993; 36( 9): 802-807.
35. Schmidt AM, Weidman E, Lalla E, et al. Advanced glycation endproducts( ages) induce oxidant stress in the gingiva: A potential mechanism underlying accelerated periodontal disease associated with diabetes. J Periodontal Res. 1996; 31( 7): 508-515.
36. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: Mechanisms and insights into therapeutic modalities. Ann Periodontol. 2001; 6( 1): 113-118.
37. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products( rage). J Clin Invest. 2001; 108( 12): 1853- 1863.
38. Sajithlal G, Huttunen H, Rauvala H, Munch G. Receptor for advanced glycation end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma cells. J Biol Chem. 2002; 277( 9): 6888-6897.
39. 39. Kim W, Hudson BI, Moser B, et al. Receptor for advanced glycation end products and its Jigands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci. 2005; 1043:553-561. 40. Green JR. Bisphosphonates: Preclinical review.
Oncologist. 2004; 9 Suppl 43-13.
41. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic atp analog, adenosine 5’-( beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997; 12( 9): 1358-1367.
42. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27( 32): 5356-5362.
43. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician. 2006; 35( 10): 801-803.
44. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol. 2007; 78( 3): 584- 594.
45. Pirih FQ, Zablotsky M, Cordell K, McCauley LK. Case report of implant placement in a patient with paget’ s disease on bisphosphonate therapy. J Mich Dent Assoc. 2009; 91( 5): 38-43.
46. Torres J, Tamimi F, Garcia I, et al. Dental implants in a patient with paget disease under bisphosphonate treatment: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107( 3): 387-392.47.
47. Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103( 6): 780- 786.
48. Tallarico M, Canullo L, Xhanari E, Meloni SM. Dental implants treatment outcomes in patient under active therapy with alendronate: 3-year follow-up results of a multicenter prospective observational study. Clin Oral Implants Res. 2016; 27( 8): 943-949.
49. Al-Sabbagh M, Robinson FG, Romanos G, Thomas MV. Osteoporosis and bisphosphonate-related osteonecrosis in a dental school implant patient population. Implant Dent. 2015; 24( 3): 328-332.
50. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008; 66( 5): 1022-1024.
51. Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol. 2007; 78( 9): 1664-1669.
52. Torricelli P, Fini M, Giavaresi G, Giardino R. Human osteoblast cultures from osteoporotic and healthy bone: biochemical markers and cytokine expression in basal conditions and in response to 1,25( OH) 2D3. Artif Cells Blood Substit Immobil Biotechnol. 2002; 30( 3): 219-227.
53. Nih consensus development panel on osteo-porosis prevention, diagnosis, and therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001; 94( 6): 569-573.
54. Wong MM, Rao LG, Ly H, et al. In vitro study of osteoblastic cells from patients with idiopathic osteoporosis and comparison with cells from non-osteoporotic controls. Osteoporos Int. 1994; 4( 1): 21-31.
55. Neidlinger-Wilke C, Stalla I, Claes L, et al. Human osteoblasts from younger normal and osteoporotic donors show differences in proliferation and tgf beta-release in response to cyclic strain. J Biomech. 1995; 28( 12): 1411-1418.
56. Abraham A, Cohen A, Shane E. Premenopausal bone health: Osteoporosis in premenopausal women. Clin Obstet Gynecol. 2013; 56( 4): 722-729.
57. Corina M, Vulpoi C, Branisteanu D. Relationship between bone mineral density, weight, and estrogen levels in pre and postmenopausal women. Rev Med Chir Soc Med Nat Iasi. 2012; 116( 4): 946-950.
58. Erdogan O, Shafer DM, Taxel P, Freilich MA. A review of the association between osteoporosis and alveolar ridge augmentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104( 6): 738 e731-713.
59. 59. Holahan CM, Koka S, Kennel KA, et al. Effect of osteoporotic status on the survival of titanium dental implants. Int J Oral Maxillofac Implants. 2008; 23( 5): 905- 910.
60. Javed F, Vohra F, Zafar S, Almas K. Significance of osteogenic surface coatings on implants to enhance osseointegration under osteoporotic-like conditions. Implant Dent. 2014; 23( 6): 679-686.
61. Krennmair G, Seemann R, Piehslinger E. Dental implants in patients with rheumatoid arthritis: Clinical outcome and peri-implant findings. J Clin Periodontol. 2010; 37( 10): 928-936.
62. Weinlander M, Krennmair G, Piehslinger E. Implant prosthodontic rehabilitation of patients with rheumatic disorders: a case series report. Int J Prosthodont. 2010; 23( 1): 22-28.
63. Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol. 1987; 64( 4): 379-390.
64. Schoen PJ, Raghoebar GM, Bouma J, et al. Prosthodontic rehabilitation of oral function in head-neck cancer patients with dental implants placed simultaneously during ablative tumour surgery: an assessment of treatment outcomes and quality of life. Int J Oral Maxillofac Surg. 2008; 37( 1): 8-16.
65. Schoen PJ, Raghoebar GM, Bouma J, et al. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: effects of hyperbaric oxygen therapy. Oral Oncol. 2007; 43( 4): 379- 388.
66. August M, Bast B, Jackson M, Perrott D. Use of the fixed mandibular implant in oral cancer patients: a retrospective study. J Oral Maxillofac Surg. 1998; 56( 3): 297-301.
67. Zen Filho EV, Tolentino Ede S, Santos PS. Viability of dental implants in head and neck irradiated patients: a systematic review. Head Neck. 2016; 38 Suppl 1: E2229- 40.
44 Stoma Edu J. 2017; 4( 1): 39-45. http:// www. stomaeduj. com